Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

Presentations

KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management

Listen to Presentation

H.C. Wainwright 8th Annual MASH Investor Conference

Listen to Presentation

H.C. Wainwright 26th Annual Global Investment Conference

Listen to Presentation

Corporate Presentation

Download the Presentation

EASL Congress Presentation

Download the Presentation

LPCN 2401 Presentation Study Results

Download the Presentation

AASLD Presentation 11/13/2023

Download the Presentation

AASLD Poster 11/13/2023

Download the Presentation

LPCN 1154 Topline Results - PK Bridge Clinical Study

Download the Presentation

LPCN 1144 Presentation-OLE Topline Results

Download the Presentation

LPCN 1144 Presentation-LiFT Topline 36 Week Results

Download the Presentation

LPCN 1144 LiFT 12 Week Study Results

Download the Presentation

LPCN 1148 Presentation

Download the Presentation

LPCN 1148 Phase 2 Study Topline Results

Download the Presentation

LPCN 1144 Presentation

Download the Presentation